GC Pharma (KRX: 006280), a South Korean biopharmaceutical company, has established Curevo Inc, a new Seattle-based company, it was reported yesterday.

The new company is intended to support GC Pharma's vaccine development activities.

GC Pharma builds a strategic collaboration and partnership with global health organisations IDRI (Infectious Disease Research Institute) and MIBR (Mogam Institute for Biomedical Research) to setup the new company. The new company will bring together GC Pharma's commercial scale vaccine development expertise and deep understanding of protein science with IDRI and MIBR's scientific expertise in vaccine, adjuvant and formulation development. Initial work will focus on advancing an innovative vaccine candidate against shingles to clinical stage.